Peng-Fei Wang,Han-Yue Qiu,Hai-Liang Zhu
Peng-Fei Wang
Introduction: As a key element in arguably the most important pathway MAPK signaling, the BRAF kinase gives rise to severe diseases including cancers when pathologically activated. Extensive research on BRAFi (BRAF inhibitor) has been carri...
Correction [0.03%]
改正通知书
Published Erratum
Expert opinion on therapeutic patents. 2019 Jul 4:1-7. DOI:10.1080/13543776.2019.1639316 2019
mGluR2 positive allosteric modulators: an updated patent review (2013-2018) [0.03%]
代谢型谷氨酸受体2(mGluR2)正向别构调节剂的专利回顾(2013-2018)
Andrés A Trabanco,José Manuel Bartolomé,José María Cid
Andrés A Trabanco
Introduction: Positive allosteric modulation of mGlu2 has attracted much interest as an alternative approach to classical orthosteric receptor activation. Two mGlu2 PAMS have advanced into the clinic. The results obtained...
Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1 [0.03%]
针对EP3356411A1的抗TIM3/PD-1双特异性抗体癌症免疫治疗方法的专利分析
Irma Herrera-Camacho,Maricruz Anaya-Ruiz,Martin Perez-Santos et al.
Irma Herrera-Camacho et al.
Introduction: TIM3 and PD-1 are checkpoint inhibitors in cancer that coordinate the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the a...
Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1 [0.03%]
OX-40激动剂与PD-L1拮抗剂联合治疗癌症的专利分析：US2018256711A1
Martin Perez-Santos,Maricruz Anaya-Ruiz,Irma Herrera-Camacho et al.
Martin Perez-Santos et al.
Introduction: OX40 is checkpoint inhibitor in cancer that coordinates the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of O...
A patenting perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications [0.03%]
从专利角度分析人中性粒细胞弹性蛋白酶（HNE）抑制剂（2014-2018）及其治疗应用
L Crocetti,M T Quinn,I A Schepetkin et al.
L Crocetti et al.
Introduction: Human neutrophil elastase (HNE) is involved in a variety of serious chronic diseases, especially cardiopulmonary pathologies. For this reason, the regulation of HNE activity represents a promising therapeuti...
Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018) [0.03%]
糖尿病肽基脯氨酰肽酶Ⅳ抑制剂的作用机制及专利布局(2015-2018年)
Hidayat Hussain,Ghulam Abbas,Ivan R Green et al.
Hidayat Hussain et al.
Introduction: Dipeptidyl peptidase 4 (DPP-4) belongs to the family of serine proteases and is involved in the degradation of GLP-1 and GIP hormones, which enhance the production and release of insulin. Targeting DPP-4 inh...
Sabina Zamanova,Ahmed M Shabana,Utpal K Mondal et al.
Sabina Zamanova et al.
Introduction: The physiologic importance of fast CO2/HCO3- interconversion in various tissues requires the presence of carbonic anhydrase (CA, EC 4.2.1.1). Fourteen CA isozymes are present in humans, all of them being use...
A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent [0.03%]
维奈托克——一种选择性Bcl-2抑制剂的专利文献综述：探索新型化疗药物的治疗潜力
Nina Žigart,Zdenko Časar
Nina Žigart
Introduction: Studies presented in patents show that a novel chemotherapeutic agent, venetoclax, might be useful in additional therapeutic indications. Venetoclax is approved in America for the treatment of patients with ...
A patent review of FGFR4 selective inhibition in cancer (2007-2018) [0.03%]
2007年至2018年FGFR4选择性抑制的专利分析
Alvaro Quintanal-Villalonga,Irene Ferrer,Sonia Molina-Pinelo et al.
Alvaro Quintanal-Villalonga et al.
Introduction: FGFR4 is a tyrosine kinase receptor which, under physiological conditions, is activated upon ligand binding in a highly regulated manner. This triggers downstream signaling related to proliferation and apopt...